Lindsey Shapiro, PhD, science writer —

Annovis Bio anticipates an interim data analysis from a Phase 3 trial of its therapeutic candidate buntanetap in people with early-stage Parkinson’s disease will be possible by mid-year, based on current trial enrollment. By then, there will likely be enough patients who’ll have received at least two months…

People with REM sleep behavior disorder (RBD) — an early nonmotor symptom of Parkinson’s disease — were significantly more likely than others to wrongly think their sense of smell was normal when olfactory deficits were evident, a small study found. Parkinson’s patients with RBD also had a diminished sense…

A 12-week electroacupuncture (EA) regimen in Parkinson’s disease patients along with standard medications was well tolerated and led to improved motor function and some relief from constipation, a recent study showed. Patients also reported gains in quality of life compared with those only receiving standard of care medications. “Our…

Neurocrine Biosciences has acquired rights to Voyager Therapeutics’ experimental gene therapy program for Parkinson’s disease associated with mutations in the GBA1 gene and for other GBA1-mediated diseases. The collaboration agreement also includes three gene therapy programs for rare diseases of the central nervous system (CNS;…

One year of treatment with Duopa, a levodopa/carbidopa intestinal gel, led to fast and sustained reductions in motor fluctuations and improved symptom control throughout the day among people with advanced Parkinson’s disease. That’s according to new analyses of data from a earlier large-scale Phase 3 clinical trial that…

Better adherence to Mediterranean-style diets is associated with lower patient-reported symptom severity in people with Parkinson’s disease, according to a study of more than 1,000 patients. Between the two evaluated diets — the Mediterranean (MEDI) and the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) — the MIND diet was…

Golexanolone, an investigational small molecule from Umecrine Cognition, reversed cognitive and motor symptoms in a rat model of Parkinson’s disease, in addition to easing signs of fatigue, anxiety, and depression. The experimental therapy is in clinical development for hepatic encephalopathy and primary biliary cholangitis, two conditions marked by…

Throughout 2022, Parkinson’s News Today brought you daily coverage of the latest scientific breakthroughs and treatment advancements related to Parkinson’s disease. Here are the 10 most-read articles of 2022, with a brief description of what made them interesting and relevant to the Parkinson’s community. We look forward to continuing…

Treatment with CST-103, CuraSen Therapeutics’ investigational oral molecule, safely led to cognitive improvements in people with Parkinson’s disease or mild cognitive impairment (MCI), according to top-line data from a Phase 2 clinical trial. By combining the CST-103, which is able to enter the brain, with a molecule…

A family of proteins called Piwis and the tiny regulatory RNA molecules they interact with — Piwi-interacting RNA (piRNA) — are critical for the formation of new neurons in the adult brain, according to recent research in mice. Data showed that depletion of a specific Piwi protein, called Mili, in…